|
|
Volumn 10, Issue 7, 2009, Pages 647-648
|
|
Lenalidomide for the treatment of relapsed multiple myeloma.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DRUG DERIVATIVE;
LENALIDOMIDE;
THALIDOMIDE;
BIOMEDICAL TECHNOLOGY ASSESSMENT;
COST BENEFIT ANALYSIS;
ECONOMICS;
HEALTH CARE ORGANIZATION;
HUMAN;
MULTIPLE MYELOMA;
NOTE;
QUALITY ADJUSTED LIFE YEAR;
RECURRENT DISEASE;
UNITED KINGDOM;
ANTINEOPLASTIC AGENTS;
COST-BENEFIT ANALYSIS;
GREAT BRITAIN;
HEALTH CARE RATIONING;
HUMANS;
MULTIPLE MYELOMA;
QUALITY-ADJUSTED LIFE YEARS;
RECURRENCE;
TECHNOLOGY ASSESSMENT, BIOMEDICAL;
THALIDOMIDE;
MLCS;
MLOWN;
|
|
EID: 67651046440
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/s1470-2045(09)70169-x Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
